While its safety profile was consistently favorable, the largest Phase IIb trial failed to show statistical significance for weight loss, and commercial development was halted in 2007.[2] Despite this, interest in AOD-9604 has continued in the compounding pharmacy and integrative medicine space, particularly given its safety data, its lack of IGF-1 stimulation, and emerging research around joint health
The cells were washed with standard 2 mM Hanks Balanced Salt Solution (HBSS
In neuronal senescence model studies, the active ingredient of the product can cross the blood-brain barrier (and act directly on neurons in vitro), increase NAD+ levels in nerve cells, protect mitochondrial function, reduce neuronal apoptosis, and promote the synthesis and release of neurotransmitters (such as dopamine and acetylcholine), thereby improving signal transduction in nerve cells
Smaller meals
Combine topical on the face with SubQ GHK-Cu injection for full-spectrum support
